The WHO (World Health Organization) on Tuesday approved the emergency use of Coronavac, developed by the Chinese laboratory Sinovac and produced in Brazil by the Butantan Institute. It is the now the eighth vaccine to be listed on WHO’s emergency use listing.

Coronavac recommended use is for adults 18 years of age or older, on a two-dose schedule 2 to 4 weeks apart. WHO’s Director-General, Tedros Adhanom, said Sinovac’s Coronavac was found to be safe, effective and quality assured following two doses of the inactivated vaccine.

According to WHO, the easy storage requirements of Coronavac make it suitable for low resource settings.